Wenseng “Wendy” Pan, J.D. & Ph.D.

• R-Bridge Healthcare Investment Advisory, Ltd. on its $60 million non-recourse loan agreement with Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK). This transaction marks the first Chinese royalty-based financing.
• OncoImmue in its sale to Merck for an upfront payment of $425 million in cash, plus sales-based milestones as well as regulatory milestones, as well as pre-sale restructuring and asset spin-off.
• Allogene in forming a first-of-its kind joint venture with Overland Pharmaceuticals (backed by Hillhouse) to develop and commercialize allogeneic CAR-T to patients in Greater China and certain South East Asian countries and Overland’s $117 Million investment in the JV and Allogene’s licensing to the JV.
• Regenacy Pharmaceuticals in forming a joint venture with 3E Capital in China, following 3E Capital’s equity investment in Regenacy. 
• Impact Therapeutics in forming a joint venture with Junshi Biosciences in China to develop and commercialize a PARP inhibitor for the treatment of cancers in Greater China.
• Xynomic in its merger with Bison Capital Acquisition Corp., a SPAC, in a Nasdaq IPO through a reverse take-over.*
• Harbour BioMed in its financing by Advantech and Legend Capital and its subsequent acquisition of Harbour Antibodies BV.*
• Lundbeck in its acquisition of Ovation Pharmaceuticals.*
• LYFE Capital in its sale of shares in Hangzhou Kangji Medical to TPG Asia.*
• Fresenius in its acquisition of calcitriol injectable asset from Xanodyne Pharmaceuticals.*
• Ikaria in its sale of INOvent® to GE Healthcare Systems.*
• Arch and Venrock in Hua Medicine’s $50m Series C financing.*
• Mevion, a U.S. medical device company, in forming a joint venture with Hopu and Yuanming.*
• BGI in its acquisition of Complete Genomics, Inc. through a tender offer.*
• K&L Consulting in its merger with Fountain Medical.*
• Tasly Pharmaceutical Holdings in forming a joint venture with Herbalife.*
• Aland Nutrition Holding Limited in its acquisition of Zhejiang Catalent Jiangyuantang Biotechnology from Catalent Singapore.*
• Catalent in establishing a joint venture with Shangpharma.*
• Charles River in acquiring 75% ownership and forming a joint venture with Vital River.*
• Stiefel (a GlaxoSmithKline company) in acquiring WBI-1001 from Welichem.*
• China Kanghui Holdings in its US$816 million sale to Medtronic.*
• LifeTech Scientific Corp in its global strategic partnership with Broncus Technology Inc.*
• Ambrx in its sale to a Chinese consortium consisting of Fosun, WuxiApptec, Everbright and Hopu.*
• Merck in forming a joint venture with Sun Pharmaceuticals to develop and commercialize innovative branded generic products in emerging marketing countries.
• CBC Capital in forming a joint venture with LinkedIn to launch LinkedIn’s operations in China.
• Cisco in establishing a US$ 200 million joint venture with China Electronics Software Information Service Co., Ltd
• Warner Brothers in forming a joint venture with Tencent for distributing movie titles over the internet. 

*Denotes experience prior to joining Goodwin.

• Zai Laboratory in its PIPE investment, licensing and strategic partnership transaction with Macrogenics involving four programs.
• Neupharma in out-licensing the Greater China rights to its BRAF V600E inhibitor to Henlius.
• BridGene Biosciences in its strategic research collaboration and licensing agreement with Takeda, using BridGene’s proprietary IMTAC™ to identify targets and small molecule drug candidates for Takeda to develop into therapeutic, with over $500 million potential milestone payments plus royalties. 
• I-Mab in its collaboration and license transaction with Complix to use Complix’s Alphabody platform to discover and develop antibodies against two immuno-oncology intracellular targets.
• Apollomics, Inc. in obtaining a worldwide (excluding Greater China) license from Edison Oncology, for the development and commercialization of EO1001, a protein tyrosine kinase inhibitor.
• Beijing Tide Pharmaceuticals in its out licensing agreement with Graviton Therapeutics for an aggregate upfront and milestones of over $500 million.
• Hinova in obtaining an exclusive license for the development, manufacturing and commercialization of AMC303 in oncology in the Greater China region.
• HiFiBio Therapeutics in its collaboration and licensing transaction with Kite for AML.
• I-Mab Biopharma in its licensing and strategic partnership transaction with AbbVie for its CD-47 program for up to $1.94bn, including $180m upfront payment.
• RTW in a series of transactions with Cytokinetics, including Ji Xing, a biotech company backed by RTW, in obtaining an exclusive license from Cytokinetics, to develop and commercialize CK-274 in Greater China as well as equity investment in Cytokinetics and acquisition of royalty stream from Cytokinetics.
• TransThera in granting an exclusive license to LG Chem under its rights for the development and commercialization of TransThera’s TT-01025 outside Greater China and Japan.
• MyoKardia, Inc. (Nasdaq: MYOK) in granting LianBio an exclusive license and forming a strategic collaboration to develop and commercialize mavacamten in China and other Asian territories.
• EpicenRx in its exclusive license agreement with Sciclone to co-develop and commercialize RRx-001, for the treatment of cancer in Greater China.
• Laekna Therapeutics in obtaining from Novartis an exclusive global license on FAZ053.
• Cloudbreak Bio-Pharmaceutical in its license agreement with China Grand Pharmaceutical related to CBT-001.
• I-Mab in its strategic alliance with Kalbe Genexine Biologics, a joint venture of Kalbe Farma Tbk and Genexine, Inc. for the commercialization of two I-Mab discovered product candidates.
• Flexion Therapeutics, Inc. in its exclusive license agreement with Hong Kong Tainuo Pharma Ltd. and Jiangsu Tainuo Pharmaceutical Co. Ltd. for the development and commercialization of Flexion’s product ZILRETTA® in Greater China.
• a Chinese biotech company in obtaining global (ex-Japan) rights to a Phase II oncology program from a Japanese pharmaceutical company.
• Shenzhen Salubris in its licensing and collaboration transaction with Japan Tobacco to obtain an exclusive license under JT’s intellectual property rights related to a hypoxia inducible factor in the Greater China;
• A Chinese biotech company in obtaining from AstraZeneca an exclusive global license to AZD4547, a Fibroblast Growth Factor Receptors (FGFR) inhibitor for FGFR-driven cancers;
• Ambrx in its licensing and collaboration transaction with Novocodex Biopharmaceuticals to jointly develop and commercialize Ambrx’s internally developed novel site-specific antibody-drug conjugates (ADCs);
• Ambrx in entering a global research and development collaboration and license agreement with Beigene;*
• Transcenta in obtaining exclusive licenses from Eli Lilly on a portfolio of novel biotherapeutics programs;*
• Novocure in granting an exclusive license to Zai Lab;*
• Everest Medicine in obtaining from Novartis an exclusive global license on FGF401.*
• Laekna in obtaining from Novartis an exclusive global license on ASB183 and UPB795 and CFG920.*
• Suzhou Kintor in obtaining from Pfizer an exclusive, worldwide license on PF-03446962.*
• Merus N.V. in its strategic collaboration with Simcere on multiple bispecific antibodies.*
• Xinogen in its license and collaboration agreement with Angiochem on ANG1005.*
• Harbour BioMed Holdings in obtaining exclusive licenses to two antibody programs from HanAll.*
• Xynomic in obtaining exclusive global licenses to abexinostat from Abbvie and two oncology programs from Boehringer Ingelheim.*
• Armetheon in its licensing and collaboration agreement with Lee’s Pharmaceuticals on Tecarfrin.*
• The Medicines Company in its licensing and strategic partnership agreement with SynBio Pharmaceuticals Inc. for IONSYS®.*
• GlaxoSmithKline in connection with its research collaboration and license agreement with PeptiDream.*
• GlaxoSmithKline in connection with the amendment of its Research Collaboration, License and Option Agreement with Isis Pharmaceuticals.*
• Takeda in connection with its licensing and development and commercialization collaboration with Intra-Cellular Therapies in order to develop selective phosphodiesterase type 1 (PDE1) inhibitors.*
• Lundbeck in connection with its collaboration and services agreement with Zenobia Therapeutics and Vernalis (R&D) Limited for developing drug candidates that inhibit LRRK2 activity.*
• Lundbeck in its licensing and development and commercialization collaboration agreement with Kyowa Hakko Kirin regarding adenosine A2A antagonist products.*
• GlaxoSmithKline in its antisense drug collaboration with Isis Pharmaceuticals for the development and commercialization of therapeutics for rare disease and infectious diseases.*
• Valeant’s predecessor Biovail in its collaboration with Alexza Pharmaceuticals to develop and commercialize Staccato Loxapine and with Acadia Pharmaceuticals to develop and commercialize Pimavanserin.*
• Takeda in its development and commercialization collaboration and technology transfer transaction with Alnylam relating to RNAi therapeutics.*
• Shire in its development and commercialization collaboration with Alba Therapeutics for AT-1001.*
• Adolor in its strategic collaboration with Pfizer for delta opioid agonists.*
• Cardiokine in its development and commercialization collaboration with Biogen Idec for lixivaptan.* 

*Denotes experience prior to joining Goodwin.

• HiFiBiO in its $75m Series D financing co-led by Mirae Capital and B-Capital.
• Apollomics in its $124m Series C financing led by PingAn Capital.
• iNeuro in its Series A financing.
• Hightide Therapeutics in its Series B+ financing.
• AccurGen in its formation and Series Seed financing by Pharmaron.
• ORI Capital in its Series A investment in AffyImmune.*
• Alphamab in its pre-IPO restructuring and receiving over $100m investment from Advantech, PAG, China Reform, OrbiMed, Ally Bridge, etc.*
• Xynomic Pharma in its pre-IPO financing from Northern Light and other investors.*
• Perfect Ease Ventures in its convertible note investment in JHL in its going private/pre-IPO transaction.*
• Junson Capital and other investors in obtaining an exclusive China right to certain diagnostic lab services from a US diagnostic lab and related Series A equity investment in Salvoe.*
• Tasly in obtaining an exclusive China right to certain diagnostic lab services from CardioDx.*
• VMS in its investment in Profusa, a US healthcare IT company.*
• Arch and Venrock in Hua Medicine’s $50m Series C financing by Harvest Capital and other investors.*
• Ascletis Bioscience Co Ltd. in connection with  investment by Goldman Sachs.*
• Ascletis Bioscience Co Ltd. in connection with investments by investors lead by CBridge Capital.*
• Elpiscience in its Series A financing by Lily Asia Ventures.*
• Angex in its Series A financing by Lily Asia Ventures.*
• Asieris in its Series B financing by Phoenix Capital.*
• Hightide Bio in its Series A financing.*
• GP Capital, a Shanghai based Chinese VC fund, in leading the Series C investment in MicuRx.*
• OrbiMed in its Series A investment in CBT Bio, a US biotech company.*
• GenEros Bio in its bridge financing and license from National University of Singapore.*
• ZD Medical in its strategic investment in Varocto Inc.*
• Asieris Biosciences in its bridge loan and Series A financing by Taifu Capital.*
• Adagene Inc. in its Series A financing from Fidelity Biosciences, Fidelity Asia Growth, and WuXi Venture.*
• Baker/Tisch Investments LLC in connection with its investments in GeneWorks and 7TM.*
• Apollomics’ pending Hong Kong IPO.
• Ambrx’s $126m NYSE IPO
• Xynomic’s Nasdaq IPO through deSPAC.*
• Alphamab’s $350 million HK IPO.*
• Haohai Healthcare’s $305 million HK IPO.*
• A life sciences company specialized in gene sequencing in its proposed HK IPO.*
• The Goldman Sachs Group in a shelf take-down of €900 million floating rate notes and €350 million 6.5% notes.*
• Goldman, Sachs & Co. as the underwriter of Providian Financial Corporation’s shelf take-down of $350 million convertible senior notes.*
• Aon Capital Markets as the initial purchaser in a Rule 144A/ Regulation D offering of common stock and a Rule 144A/Regulation S offering of floating rate notes of Domestic in connection with an insurance securitization transaction.*
• Hayes Lemmerz  International in a Rule 144A/Regulation S offering of senior unsecured notes in connection with its Chapter 11 reorganization.*

*Denotes experience prior to joining Goodwin.